Methods and systems for treatment of neurodegenerative disease and uses thereof

Administering mast cell stabilizers like cromolyn addresses the limitations of existing ALS treatments by reducing neuroinflammation and promoting anti-inflammatory responses, thereby slowing disease progression.

WO2026015576A1PCT designated stage Publication Date: 2026-01-15PHENONET INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/036872
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-02-07
Filing Date
2025-07-08
Publication Date
2026-01-15

AI Technical Summary

Technical Problem

Current treatments for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), do not address the root cause of the disease and are limited in their neuroprotective effects, necessitating the development of additional primary and adjunct therapies.

Method used

Administering a therapeutically effective amount of a mast cell stabilizer, such as cromolyn, to inhibit neuroinflammation by reducing pro-inflammatory proteins and promoting anti-inflammatory cytokines, enhancing microglial phagocytosis, and supporting neurite growth.

Benefits of technology

The use of mast cell stabilizers effectively reduces neuroinflammation and slows disease progression in ALS patients, as evidenced by improved ALSFRS-R scores over a 4-week period.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025036872_15012026_PF_FP_ABST
    Figure US2025036872_15012026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides methods of treatment of neurodegenerative disease, such as a motor neuron disease, in subjects in need thereof. A therapeutically effective dose of a suitable mast cell stabilizer may be administered to suitable subjects, wherein the suitability of a subject is determined by the rate of progression of the disease over time or by the severity of the disease. A therapeutically effective dose of a suitable mast cell stabilizer may be administered to suitable subjects, wherein the suitability of a subject is determined by subject genotype and / or family genotypes or medical history. In certain embodiments, the therapy may comprise a cromolyn homolog salt, and suitable subjects are persons with amyotrophic lateral sclerosis (ALS). In certain embodiments, the subjects are patients with slow progressing ALS and / or the subjects have mild to moderate ALS. In certain embodiments, the subjects are persons with sporadic ALS or persons without familial ALS.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

    US20180117037A1

  • Powdered formulations of cromolyn sodium and alpha-lactose

    US20200022947A1

  • Methods and compositions for treating various disorders

    US20220152057A1